Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial — Desmond Yip (2025) | RDL Network
Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial
Sebastian Bauer, Robin L. Jones, Jean Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Ying Su, Julie Meade, Tao Wang, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich
Alice Boilève, Armelle Dufresne, Ali N. Chamseddine, Sarah Dumont, M. Brahmi, Julien Adam, Etienne Rouleau, Marie Karanian, Véronique Haddad, Matthieu Faron, Charles Honoré, Pierre Méeus, Axel Le Cesne, Jean Yves Blay, Olivier Mir
John Zalcberg, Michael C. Heinrich, Suzanne George, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, César Serrano, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Nicole Meade, V. Reichert, Kelvin Shi, Rodrigo Ruiz‐Soto, Margaret von Mehren, Jean Yves Blay
Alessandro Gronchi, Sylvie Bonvalot, A. Poveda Velasco, Dusan Kotasek, Piotr Rutkowski, Peter Hohenberger, Elena Fumagalli, Ian Judson, Antoîne Italiano, Hans Gelderblom, Frits van Coevorden, Nicolas Penel, Hans‐Georg Kopp, Florence Duffaud, David Goldstein, Javier Martín‐Broto, Eva Wardelmann, Sandrine Marréaud, B. Mark Smithers, Axel Le Cesne, Facundo Zaffaroni, Saskia Litière,
George D. Demetri, Christopher R. Garrett, Patrick Schöffski, Manisha H. Shah, Jaap Verweij, Serge Leyvraz, Herbert I. Hurwitz, Antonio López–Pousa, Axel Le Cesne, David S. Goldstein, Luis Paz‐Ares, Jean Yves Blay, Grant A. McArthur, Qiang Xu, Xin Huang, Charles S. Harmon, Vanessa Tassell, Darrel P. Cohen, Paolo G. Casali
Discussion(0)
No comments yet. Be the first to comment.